Clinical activity of irinotecan;Spectre d'activite clinique de l'irinotecan

Bulletin du Cancer

Volumn 85, Issue SPEC. ISS. DEC., 1998, Pages 21-25

  Cottu, Paul Henri ^a   Extra, Jean Marc ^b   Lerebours, Florence ^a   Espie, Marc ^a   Marty, Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Irinotecan; Spectrum of activity

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; RALTITREXED; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; STOMACH CARCINOMA; SURVIVAL TIME; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; ADULT; BLOOD DISEASE; BREAST TUMOR; BRONCHUS TUMOR; CHILD; CLINICAL TRIAL; DIGESTIVE SYSTEM TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; FEMALE GENITAL TRACT TUMOR; MALE; NEOPLASM; REMISSION; SMALL CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRONCHIAL NEOPLASMS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CHILD; CLINICAL TRIALS; DIGESTIVE SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032241765     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985 ; 54 : 665-97.
2. Pommier Y. Eukaryotic DNA topoisomerase I : genome gatekeeper and its intruders, camptothecins. Semin Oncol 1996 ; 23 (1 suppl. 3) : 3-10.
3. Thomsen B, Mollerup S, Bonven BJ, Blocker H, Nielsen OF, Westergaard O. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin. EMBO J 1987 ; 6 : 1817-23.
4. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin : evidence for binding to an enzyme-DNA complex. Biochemistry 1989 ; 28 : 4629-38.
5. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989 ; 49 : 5016-22.
6. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989 ; 49 : 5077-82.
7. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996 ; 23 (1 suppl. 3) : 11-20.
8. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993 ; 5 : 467-74.
9. Armand JP, Extra JM, Catimel G, Abigerges D, Marty M, Clavel M. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996 ; 7 : 837-42.
10. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995 ; 13 : 210-21.
11. Merrouche Y, Fxtra JM, Abigerges D, Bugat R, Catimel G, Suc E, et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients : a feasibility study. J Clin Oncol 1997 ; 15 : 1080-6.
12. 2 given every-other-week in previously treated colorectal cancer patients. Proc Annu Meet Am Soc Clin Oncol 1998 ; 17 : A1092.
13. Takimoto CH, Morrison G, Guemei A, Band RA, Cottrell J, Monahan BP, et al. A phase I and pharmacologic study of irinotecan administered as a 96 hr infusion weekly for two consecutive weeks to adult patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol 1998 ; 17 : A971.
14. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer : clinical efficacy and safety profile. Semin Oncol 1996 ; 23 (1 suppl. 3) : 34-41.
15. Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996 ; 32A (suppl. 3) : S13-7.
16. Irinotecan : dossier d'enregistrement.
17. Guichard S, Hennebelle I, Cussac D, Bugat R, Canal P. In vivo evaluation of the irinotecan (CPT-11)/5-fluorouracil (5FU) combination. Proc Annu Meet Am Assoc Cancer Res 1997 ; 38 : A512.
18. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil : a promising combination for therapy of colorectal cancer. Eur J Cancer 1996 ; 32A (suppl. 3) : S24-31.
19. Saltz L, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996 ; 14 : 2959-67.
20. Falcone A, Allegrini G, Masi G, Andreuccetti M, Danesi R, Di Paolo A, et al. Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion : a phase I study with pharmacokinetic ; DNA damage and topoisomerase I/DNA complexes evaluation in chemotherapy naive metastatic colorectal cancer patients. Proc Amer Soc Clin Oncol 1998 ; 17 : (abstract) 1493.
21. Lokiec F, Wasserman E, Santoni J, Mahjoubi M, Misset JL, Cvitkovic E. Pharmacokinetics (PK) of the irinotecan (CPT-11)/oxaliplatin (LOHP) combination : preliminary data of an ongoing phase I trial. Proc Annu Meet Am Assoc Cancer Res 1997 ; 38 : A514.
22. Chevallier B, Lhomme C, Dieras V, Vennin P, Chauvergnes J, et al. Phase II trial of CPT11 in advanced cervical carcinoma. Proc Amer Soc Clin Oncol 1995 ; 14 : 267, AB737.
23. Potkul RK, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ. Irinotecan (CPT11) in advanced squamous cell carcinoma of the cervix (phase II). Proc Annu Meet Am Soc Clin Oncol 1995 ; 14 : A785.
24. Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997 ; 15 : 625-31.
25. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Gan To Kagaku Ryoho 1994 ; 21 : 1033-8.
26. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997 ; 15 : 921-7.
27. Nitta T, Takada M, Hirashima T, Tamanoi M, Masuda N, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Proc Annu Meet Am Assoc Cancer Res 1993 ; 34 : A1227.
28. Douillard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1995 ; 14 : A1118.
29. Kobayashi K, Soma T, Shinbara A, Kudoh K, Kabe J, Hino M, et al. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) by divided administration in patients with non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1996 ; 15 : A1169.
30. Mori K, Hirose T, Machida S, Yokoyama K, Tominaga K. A phase I study of irinorecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 1997 ; 33 : 503-5.
31. Goto K, Nishiwaki Y, Saijo N, Nakabayashi T, Kawakami Y, Fujita A, et al. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC) : Japanese Clinical Oncology Group (JCOG) trial. Proc Annu Meet Am Soc Clin Oncol 1995 ; 14 : A1108.
32. Mogi H, Hasegawa Y, Watanabe A, Nomura F, Saka H, Shimokata K. Combination effects of cisplatin ; vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol 1997 ; 39 : 199-204.
33. Nakagawa K, Yamamoto N, Kudoh S, Yamada M, Negoro S, Takeda K, et al. Irinotecan (CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (Trt) for unresectable ; stage III non-small cell lung cancer (NSCLC)-preliminary results. Proc Annu Meet Am Soc Clin Oncol 1995 ; 18 : A1108.
34. Takeda K, Negoro S, Masuda N, Kudoh S, Sugiura T, Shimokara H, et al. Phase I/II study of docetaxel (Doc) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1997 ; 16 : A1742.
35. Bahadori HR, Ogretmen B, Rocha Lima CM, Green MR, Safa AR. Evaluation of irinotecan (CPT-11) and gemcitabine (G) as single agents and in combination in small-cell lung cancer cells. Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A722.
36. Rothenberg ML. CPT-11 : an original spectrum of clinical activity. Semin Oncol 1996 ; 23 (1 suppl. 3) : 21-6.
37. Sugiura S, Saka H, Ando M, Watanabe A, Nomura F, Yamamoto M, et al. Phase II and pharmacokinetic (PK)/pharmacodynamic (PD) study of carboplatin (CBDCA) and irinotecan (CPT11) in patients with small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A1092.
38. Sakata Y, Wakui A, Nakao I, Futatsuki K, Kambe M, Yoshino M, et al. A late phase II study of irinotecan (CPT-11) in advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol 1993 ; 12 : A633.
39. O'Reilly E, Stuart K, Kemeny N, Steger C, Raeburn L, Sanz-Altamira P, et al. A phase II trial of irinotecan (CPT-11) in patients with advanced hepatocellular carcinomas (HCC). Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A152.
40. Enzinger P, Ilson D, Saltz L, O'Reilly E, Gollub M, DeGroff J, et al. A phase II trial of cisplatin and irinotecan in patients with advanced esophageal cancer. Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A1167.
41. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer. Gan To Kagaku Ryoho 1994 ; 21 : 1017-24.
42. Données personnelles.
43. Sugiyama T, Nishida T, Ushijima K, Kumagai S, Yskushiji M. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or merastatic ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1996 ; 15 : A796.
44. Gollerkeri A, Burtness B, Peccerillo K, Murren JR. Dose escalation trial of irinotecan (I) plus paclitaxel (P) in patients (Pts) with advanced cancer. Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A1837.
45. Ota K, Ohno R, Shirakawa S, Masaoka T, Okada K, Ohashi Y, et al. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. Gan To Kagaku Ryoho 1994 ; 21 : 1047-55.
46. Blaney S, Berg S, Pratt C, Vietti T, Sullivan J, Murry D, et al. A phase I study of irinotecan in pediatric patients : a Pediatric Oncology Group study. Proc Annu Meet Am Soc Clin Oncol 1998 ; 18 : A1085.